NanoSphere Cannabis International To Represent Company’s Technology
in Global Market, Outside the United States
Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) (“NanoSphere” or “the
Company”), is taking its cannabis business global with the formation of
a wholly owned subsidiary, NanoSphere Cannabis International (“NCI”).
NanoSphere developed a patented process using nanoparticles to deliver
medicines, nutraceuticals and cosmeceuticals directly through the skin
or the mucous membrane into the blood stream. The technology allows for
more precise dosing, faster onset, and better bioavailability of
medicines or cannabis.
The new Vancouver-based company will be charged with the task of
licensing NanoSphere’s groundbreaking technology in countries where
medical or recreational cannabis is legal.
Gary Symons, currently CEO at Deep Incite Consulting and Director of
Communications at Delta 9 Cannabis, has been named President and Chief
Operating Officer of NCI. Symons comes to the cannabis business with an
unusual skill set. He was an investigative and crime reporter for 23
years, most recently with CBC News, and then founded and ran VeriCorder
Technology until it was acquired in 2012.
Mr. Symons has worked in the cannabis industry since 2012 as a
financier, consultant and advisor to several cannabis companies,
including Delta 9 Cannabis Inc., (TSXV: NINE) (OTC: VRNDF) and also owns
a boutique finance and communications firm. Mr. Symons was involved in
more than $50 million in financing for the sector during that time, and
has negotiated dozens of international licensing deals over his career.
NanoSphere CEO and Chairman Robert Sutton says the NCI operation is
being formed to focus specifically on the global cannabis industry.
“The NCI operation is being formed in Canada to focus specifically on
Canadian and Global opportunities available in the cannabis industry,”
Sutton explained. “Leaders in the industry from around the world look to
companies in the Canadian legal market for guidance on regulations and
product development. It is important that the NanoSphere delivery system
be represented in these discussions to aid in our global expansion.”
“The formation of NCI is partly designed to help foster the partnership
between NanoSphere and Delta 9 Cannabis Inc.,” adds Symons. “We are
working to finalize our agreements with Delta 9 to be our Canadian
partner and holder of the Master License for our Cannabis Delivery
System. The unique grow pod system developed by Delta 9, combined with
our technology, would give both companies a means to rapidly expand into
global markets with a product that no other company can match.”
NCI and Delta 9 are currently preparing applications to Health Canada
for a suite of products that will provide a safer and healthier way to
consume cannabis, both for the medical and recreational cannabis markets.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining
several licensing opportunities via a rigorous evaluation process. For
more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in
the creation of the patented NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of
supplements, nutraceuticals and over-the-counter medications for the
cannabis, pharmaceutical and animal health industries, and beyond.
Covered by U.S. Patent No. 10,028,919 and U.S. Patent No. 9,925,149,
NanoSphere Delivery System™ represents one of the most important
developments for advancing the non-invasive and user-friendly delivery
of biological agents in over 25 years. NanoSphere was named for the 2018
Frost and Sullivan Technology Innovation Award and was recognized by
ACQ5 Global Awards as Company of the Year for Nano-Biotechnology,
Innovative Company of the Year for Healthcare, and its CEO Robert Sutton
was honoured as Gamechanger of the Year.
For more information on NanoSphere, please visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world’s first and only
scientifically proven nanoparticle delivery system in cannabis. Evolve’s
pioneering product, Transdermal NanoSerum™, is a fast-acting,
ultra-strength transdermal formula infused with nano-encapsulated
cannabis and cannabis extracts. NanoSerum™ immediately penetrates the
skin to deliver direct-focused results and intelligently carries a full
spectrum of cannabinoids and phytochemicals to receptors throughout the
body for systemic healing. Evolve Formula products leverage NanoSphere
Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere
Delivery System™ is a revolutionary platform using nanotechnology in the
biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health
industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/.
Follow us on Facebook,
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Readers are advised to rely on their own evaluation of such risks and
uncertainties and should not place undue reliance on forward looking
statements. Any forward looking statements are made as of the date of
this news release, and the Company assumes no obligation to update the
forward looking statements, or to update the reasons why actual events
or results could or do differ from those projected in the forward
looking statements, whether as a result of new information, future
events or otherwise.
NanoSphere Health Sciences, Inc.On behalf of the BoardRobert
Sutton, 720-520-4282Chairman and CEO[email protected]orInvestors:Victor
Goncalves, 204-997-5517Executive Vice President[email protected]orThe
Rosen GroupGabrielle Wesseldyk, 212-255-0945[email protected]